Vilobelimab is a Monoclonal Antibody owned by InflaRx, and is involved in 10 clinical trials, of which 9 were completed, and 1 is ongoing.
IFX-1 is humanized monoclonal antibody that targets complement activation product C5a. Complement C5 is comprised of alpha and beta polypeptide chains that are linked by a disulfide bridge. C5a is an anaphylatoxin that is derived from the alpha polypeptide via cleavage with a convertase. C5a possesses spasmogenic and chemotactic activity and stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation. IFX-1 by specifically targeting C5a eliminates its effects. IFX-1 leaves C5b-9 intact.
The revenue for Vilobelimab is expected to reach a total of $821m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Vilobelimab NPV Report.
Vilobelimab (IFX-1) is under development for the treatment of advanced or metastatic cutaneous squamous cell carcinoma (cSCC), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), anti-neutrophil cytoplasmic antibody-associated vasculitis, septic organ dysfunction, hidradenitis suppurativa, systemic inflammatory response syndrome (SIRS) induced organ dysfunction (sepsis, septic shock, inflammation, multiple organ dysfunction), acute lung injury, pyoderma gangraenosum, chronic inflammation, cancer and coronavirus disease 2019 (COVID-19). It is administered through intravenous route. The drug candidate is a humanized monoclonal antibody. It was under development for community-acquired pneumonia.
It was under development for anti-neutrophil cytoplasmic antibody-associated vasculitis and hidradenitis suppurativa.
InflaRx is a clinical-stage bio pharmaceutical company that develops therapies in the field of acute and chronic inflammation. The company offers the development of monoclonal antibodies targeting activation products of the complement system for application in threatening inflammatory diseases and certain orhan drug indications. Its pipeline products includes IFX-1 and IFX-2. InflaRx operates in various research and development programs in life science sectors. The company offers antibodies that are able to fulfil requirements determined by InflaRx for generation of suitable drug candidates. It offers research services through collaboration with universities and biotech companies. InflaRx is headquartered in Jena, Germany.
The operating loss of the company was EUR47.6 million in FY2021, compared to an operating loss of EUR33.9 million in FY2020. The net loss of the company was EUR45.6 million in FY2021, compared to a net loss of EUR34 million in FY2020.
Quick View – Vilobelimab
|Highest Development Stage|